Ipca Laboratories is currently trading at Rs 266.50, up by 0.45 points or 0.17% from its previous closing of Rs 266.05 on the BSE.
The scrip opened at Rs 260.05 and has touched a high and low of Rs 269.90 and Rs 260.05 respectively. So far 11067 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 351.00 on 14-Jun-2011 and a 52 week low of Rs 255.10 on 10-Mar-2011.
Last one week high and low of the scrip stood at Rs 284.70 and Rs 260.05 respectively. The current market cap of the company is Rs 3344.42 crore.
The promoters holding in the company stood at 46.05% while Institutions and Non-Institutions held 32.28% and 21.67% respectively.
Ipca Laboratories has received an approval for amalgamation of Tonira Pharma with the company with effect from April 01, 2011 being the appointed date through a scheme of amalgamation. The board at its meeting held on September 17, 2011 has considered and approved the same. However, the proposed scheme of amalgamation will be subject to all necessary permissions and approvals, as may be required.
Further, the scheme envisages an exchange ratio of six equity shares of Rs 2 each fully paid-up of Ipca Laboratories for every one hundred equity shares of Rs 10 each fully paid-up of Tonira Pharma. The exchange ratio is based on the joint valuation made by Natvarlal Vepari & Company, Chartered Accountants and G. M. Kapadia & Company, Chartered Accountants.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Tonira Pharma is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates. Tonira undertakes contract synthesis both on exclusive and non-exclusive basis. The company has the capability to provide contract research and manufacturing services to its customers.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1814.50 |
| Dr. Reddys Lab | 1340.80 |
| Cipla | 1476.45 |
| Lupin | 2160.20 |
| Zydus Lifesciences | 972.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
